PubRank

Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)

Clinical Trial ID NCT01626495

PubWeight™ 43.06‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01626495

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013 10.63
2 Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014 8.21
3 Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014 2.84
4 Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013 2.39
5 Chimeric antigen receptor therapy for cancer. Annu Rev Med 2013 1.94
6 Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013 1.91
7 Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol 2013 1.64
8 Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 2014 1.61
9 Driving CAR T-cells forward. Nat Rev Clin Oncol 2016 1.09
10 Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013 0.95
11 CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther Adv Hematol 2015 0.95
12 Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 2014 0.89
13 Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood 2016 0.87
14 Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol 2015 0.87
15 Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia 2014 0.86
16 Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev 2016 0.85
17 Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol 2015 0.84
18 Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances. Ther Adv Hematol 2015 0.82
19 Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncol 2014 0.78
20 Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors. World J Stem Cells 2015 0.78
21 Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives. Front Oncol 2013 0.77
22 Using gene therapy to manipulate the immune system in the fight against B-cell leukemias. Expert Opin Biol Ther 2015 0.77
23 Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit Care Med 2016 0.76
24 Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy. Immunotargets Ther 2015 0.75
25 Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Pediatr Blood Cancer 2015 0.75
Next 100